Antisense Nucleic Acid Synthesis Services
Antisense nucleic acid drugs (Antisense oligonucleotide drugs) are short DNA fragments of different lengths that are complementary to specific mRNA sequences. They can interfere with gene expression by forming hybrid duplexes with target mRNA. The nucleotide sequence can be complementary to the target mRNA or target DNA, inhibit or block the transcription and expression of the gene, or induce RNaseH to recognize and cleave the mRNA, making it lose its function and become a powerful tool for gene function analysis and drug development. Creative Biolabs is a professional biotechnology services platform, providing outsourced experiments for oligonucleotide synthesis research. We have professional researchers and strict quality control to ensure the synthesis of high-quality antisense nucleic acid.
- Short antisense oligonucleotides (antisense oligodeoxyncleotides, AON) artificially synthesized by solid-phase phosphoramidite method, including unmodified AON, phosphorothioate (PS), phosphodiestery (PO) and methylation modified AON.
- Artificial expression vector, including a single gene and a combined antisense expression vector of multiple genes. It uses gene recombination technology to insert the target gene sequence into the vector's promoter and terminator in reverse, and it can be continuously transcribed.
- Naturally occurring antisense nucleic acid molecules.
The synthesis process of antisense nucleic acid drugs
Phosphorous gum chemical synthesis method:
The mechanism of action of antisense RNA: Mainly manifested at the three levels of DNA replication, transcription and post-transcription, translation.
- DNA replication level: As an inhibitor of DNA replication, antisense RNA binds to primer RNA or acts on primer precursors to inhibit DNA replication.
- Transcription and post-transcription level:
Acts on the 5'end of the target m RNA to prevent the formation of the cap structure and affect the maturation of the target mRNA.
Acts on the PolyA formation site to prevent the maturation of target mRNA and its transport into the cytoplasm.
Acts on the junction of exons and introns to prevent splicing of mRNA precursors.
- Translation level:
Antisense RNA can directly bind to the SD sequence (including RBS) or coding region (mainly AUG) of the mRNA, and directly prevents the normal binding of ribosomes or directly degrades the target mRNA.
Advantages of antisense nucleic acid synthesis drugs:
- High specificity: Antisense nucleic acid drugs act on target RNA or DNA through specific base complementary pairing.
- High biological activity and abundant information: Antisense nucleic acid is a kind of information body that carries specific genetic information, and the sequence of bases can be varied and inexhaustible.
- High efficiency: directly prevent the transcription and translation of disease genes.
- Optimal drug design: Antisense nucleic acid technology essentially uses the natural sequence information of genes, and is actually the most reasonable drug design.
- Low toxicity and safety: Antisense nucleic acids have not been found to have significant toxicity. Although they may persist for a long time or a short time in vivo, they will eventually be degraded and eliminated, it avoids the risk of integrating foreign genes into host chromosomes in the case of transgenic therapy.
References
- Barkowsky Gina, Kreikemeyer Bernd, et al. Validation of Suitable Carrier Molecules and Target Genes for Antisense Therapy Using Peptide-Coupled Peptide Nucleic Acids (PNAs) in Streptococci. Methods in molecular biology. 2020.
- Brolin Camilla, Lim Ernest Wee Kiat, et al. Approaches for Systemic Delivery of Dystrophin Antisense Peptide Nucleic Acid in the mdx Mouse Model. Nucleic Acid Therapeutics. 2020.
*For Research Use Only. Not for use in diagnostic procedures.